1. Home
  2. LDP vs PCRX Comparison

LDP vs PCRX Comparison

Compare LDP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Limited Duration Preferred and Income Fund Inc.

LDP

Cohen & Steers Limited Duration Preferred and Income Fund Inc.

HOLD

Current Price

$20.28

Market Cap

618.8M

Sector

Finance

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.65

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDP
PCRX
Founded
2012
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
618.8M
1.0B
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
LDP
PCRX
Price
$20.28
$22.65
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$37.60
AVG Volume (30 Days)
61.3K
765.8K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
7.91%
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.16
Revenue
N/A
$541,533,000.00
Revenue This Year
N/A
$9.77
Revenue Next Year
N/A
$9.71
P/E Ratio
N/A
$137.44
Revenue Growth
N/A
26.04
52 Week Low
$18.38
$18.80
52 Week High
$22.05
$27.99

Technical Indicators

Market Signals
Indicator
LDP
PCRX
Relative Strength Index (RSI) 26.78 51.36
Support Level N/A $20.09
Resistance Level $21.51 $23.82
Average True Range (ATR) 0.18 1.07
MACD -0.05 -0.05
Stochastic Oscillator 3.48 53.29

Price Performance

Historical Comparison
LDP
PCRX

About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.

Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: